


# WELCOME TO PRACTICAL TUTORIALS ON HEMODYNAMIC BALANCE IN ACUTE AND ADVANCED HEART FAILURE: I.V. VASO-ACTIVE OPTIONS

on **SUNDAY** and **MONDAY**, May 26-27  
at the **Heart Failure 2019**

The use of inotropes for correcting hemodynamic dysfunction in patients with congestive heart failure has been described over many decades. However, negative or insufficient data has been collected on the effects of cardiac glycosides, catecholamines, and phosphodiesterase inhibitors on quality of life and survival. More recently, the calcium sensitizer and potassium channel opener levosimendan has been proposed as a safer inodilator. This series of tutorials focus on how to use safely and effectively levosimendan in acute and advanced heart failure.

**Refreshments will be served at each session.**

**The same program with same timings will  
be held both on Sunday and Monday.**



**SUNDAY May 26 and MONDAY May 27**

**09:15–10:15**

**Practical Tutorials 1**

**MC 3.2**

### **The Acute Heart Failure settings**

- 9:15 Guidelines and definition of AHF, therapeutic options // José Garcia-Pinilla (Malaga, Spain)
- 9:35 Role of hemodynamic active drugs, differential effects of drug families // Dirk von Lewinski (Graz, Austria)
- 9:55 Clinical practice in AHF with different etiologies // John Parisis (Athens, Greece)

**SUNDAY May 26 and MONDAY May 27**

**11:15–12:15**

**Practical Tutorials 1**

**MC 3.2**

### **The Advanced Heart Failure settings**

- 11:15 Physiological effects of vaso-active drugs in AdHF? // Piergiuseppe Agostoni (Milan, Italy)
- 11:35 Guidelines and definition of AdHF, therapeutic options // Patrick Yerly (Assens, Switzerland)
- 11:55 When does acute decompensation start? // Gerhard Pözl (Innsbruck, Austria)

**SUNDAY May 26 and MONDAY May 27**

**13:15–14:15**

**Practical Tutorials 1**

**MC 3.2**

### **Differential renal effects of vasoactive drugs**

- 13:15 Cardio-renal syndrome // Endre Zima (Budapest, Hungary)
- 13:35 Differential renal effects of levosimendan on renal function in AHF and restrictive cardiomyopathy // Alexander Reinecke (Kiel, Germany)
- 13:55 Clinical practice // Kristjan Karason (Gothenburg, Sweden)

**SUNDAY May 26 and MONDAY May 27**

**15:15–16:15**

**Practical Tutorials 1**

**MC 3.2**

### **AHF or CS as a consequence of Acute Coronary Syndrome**

- 15:15 Therapeutic options and clinical practice for ACS-induced AHF // Alejandro Recio Mayoral (Sevilla, Spain)
- 15:35 Therapeutic options and clinical practice for ACS-induced cardiogenic shock // Veli-Pekka Harjola (Helsinki, Finland)
- 15:55 Clinical practice // Dimitrios Farmakis (Athens, Greece)